Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells M3PPVmN6fG:2b4jpZ4l1gSCjc4PhfS=> NV\0OoxMPzJiaB?= MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?= NVjrPYdQOTl4NUS0NFg>
RS4-11 cells M17ubWZ2dmO2aX;uJIF{e2G7 NUnRdIlCOiCq M2S5eWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>? NXrkcpd5OTl4NUS0NFg>
CGTH-W-1 cell NYDJNY9vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHTqcItKdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDJwNkWg{txO MWTTRW5ITVJ?
SW982 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\rbFdKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvPThizszN NYOxc5VIW0GQR1XS
human EoL-1-cell cell M4Gydmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTaU4ZWUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFghdk1? NGXpeJpUSU6JRWK=
MOLM-13 cells M4O0U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWC3NkBp NYTWWmMzUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=> NWfXNFd{OjZyOEGwNlM>
KASUMI-1 cell M3z0[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJGtCW1WPST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xPjBzNjFOwG0> NUf4NotTW0GQR1XS
NCI-H1755 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3rGXGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkK3N{DPxE1? NVPrTZExW0GQR1XS
human MES-SA cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLnU5NxUW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? M3PFbHNCVkeHUh?=
human HCC1395 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTUUXdyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOESyPEDPxE1? MnfaV2FPT0WU
human D-336MG cell M{LkcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\Mc4xKdmirYnn0bY9vKG:oIHj1cYFvKERvM{O2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{W0JO69VQ>? NFO5cGZUSU6JRWK=
CHP-212 cell MnizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnYUpI2UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe3N{DPxE1? M3HGSnNCVkeHUh?=
human KM12 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\2cmlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFkzPzVizszN M2qzO3NCVkeHUh?=
A204 cell NUS3WmY3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLlTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFA2OiEQvF2= NXzad|BJW0GQR1XS
CAL-51 cell M3XGO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\ZTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=> M3nhOXNCVkeHUh?=
human A431 cell M2fNc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7RfpFKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=> NUfqVJE5W0GQR1XS
NCI-H650 cell NFznUYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnWTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF5MEig{txO NH\RWpFUSU6JRWK=
A427 cell MlzGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXqTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVkyQCEQvF2= MUDTRW5ITVJ?
human 769-P cell NHnFbJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3Xm[mlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=> M1;FTHNCVkeHUh?=
SW1710 cell MkXIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4fUbGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0> NXi4cHBKW0GQR1XS
human H4 cell NYGx[oFoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmS0TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUO5OlMh|ryP M3PHVnNCVkeHUh?=
HT-1080 cell MnXlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnpNHg2UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NkDPxE1? M{\oXnNCVkeHUh?=
human PANC-03-27 cell NHHIUFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGX4SItKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFIh|ryP MlLGV2FPT0WU
A375 cells MlqxR5l1d3SxeHnjbZR6KGG|c3H5 M1[0SVczKGh? MoH4WI95cWOrdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6xPEDPxE1? NGDrblYyQTZ3NESwPC=>
human HOP-62 cell MoK2SpVv[3Srb36gZZN{[Xl? NF[3fJRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO M2TKdnNCVkeHUh?=
human U031 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{PIZmlvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk3QThizszN NFOwVXZUSU6JRWK=
mouse BAF3 cells NIPlbWJRem:uaX\ldoF1cW:wIHHzd4F6 MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1? M1GxOlIyQTN4NUSy
human G-402 cell Ml7VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vYRmlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxOjV|IN88US=> NH7BZmJUSU6JRWK=
human G-361 cell M{\DfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUWyb|lKUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO NWnzOpQ6W0GQR1XS
NCI-H810 cell M17xWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnxRm55UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkGwNlch|ryP M4HBSnNCVkeHUh?=
NCI-H2030 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIrzOZlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkOwNFYh|ryP MVPTRW5ITVJ?
human HCT-116 cell NUfab4dUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTKTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzV4ODFOwG0> NHjTeHhUSU6JRWK=
human SNU-423 cell NG\CdW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVq5[I5QUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{[1O{DPxE1? MYrTRW5ITVJ?
human SCC-4 cell NHP4[3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmH1TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlM6PjdizszN NV[zUoN2W0GQR1XS
human SW48 cell M1;OWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;GTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= NFTkNJdUSU6JRWK=
human SF295 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{KzWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4OjV5IN88US=> NYT2c|FMW0GQR1XS
MDA-MB-231 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? NW[0NnBNW0GQR1XS
A172 cell MmXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjwUVJOUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTF3IN88US=> M3fQO3NCVkeHUh?=
human BCPAP cell Mn;vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPVg4QSEQvF2= MYLTRW5ITVJ?
human COLO-792 cell M2XzTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlWwTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjl7N{Kg{txO NYDsTW1iW0GQR1XS
human DU-145 cell MmGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\OO2lvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OTh6OTFOwG0> NHr0T4FUSU6JRWK=
NCI-H2122 cell M36xeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13uSGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkK4OUDPxE1? M4L6cnNCVkeHUh?=
human SK-UT-1 cell NEf2UmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> M4fjVXNCVkeHUh?=
LXF-289 cell NYLUdYJtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7EU21zUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkm2OUDPxE1? NYHxRVhlW0GQR1XS
human NCI-H1792 cell NF34V2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2rRUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{C5OkDPxE1? Mnq4V2FPT0WU
MCF7 cell NWm5UoY1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?= MXjTRW5ITVJ?
HCT-15 cell NIL3c2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3LTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PDN{IN88US=> MYHTRW5ITVJ?
human NCI-H358 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> NXnENXBLW0GQR1XS
human HLE cell M1Wwc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjmRop7UW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PzV{IN88US=> NHHxTWRUSU6JRWK=
human SW1088 cell NVXINZhxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXHclFmUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|N{m3JO69VQ>? M1;odHNCVkeHUh?=
human K5 cell MkTFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\xTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP M2q5PXNCVkeHUh?=
human SR cell Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4PKSWlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?= M4fuVHNCVkeHUh?=
human Calu-3 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MonQTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=> Mmj0V2FPT0WU
human SK-MEL-30 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;rdWlqUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO5PVE{KM7:TR?= MV;TRW5ITVJ?
human SW780 cell NEjOOItIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH62[nFKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> M{DVRnNCVkeHUh?=
NCI-H1563 cell MnvoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYj4cIh{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?= MYDTRW5ITVJ?
human MKN45 cell M{fWWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\kTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFE6OzFizszN MXLTRW5ITVJ?
MDA-MB-157 cell NF\IVWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPNd4JKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSyNFE2KM7:TR?= NY[5NFJoW0GQR1XS
human NCI-H522 cell M320dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFXISFVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO M{fvWnNCVkeHUh?=
human A2780 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;pdmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB|IN88US=> MYjTRW5ITVJ?
human A498 cell M4XsS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2TJS2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc3QTNizszN M{PtXXNCVkeHUh?=
human BxPC-3 cell MmrVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XSbmlvcGmkaYTpc44hd2ZiaIXtZY4hSniSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTN4NjFOwG0> NF7YXFFUSU6JRWK=
human A2058 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33RTGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=> NFLXSHdUSU6JRWK=
human PC-14 cell NUH5RYQ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXQfJN2UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO MUDTRW5ITVJ?
human KG-1 cell NVvVfWF4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXPYWGV5UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PTRzOTFOwG0> MU\TRW5ITVJ?
human A375 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?= M2nyb3NCVkeHUh?=
human SW1783 cell NVjHSmlGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|M{PyEQvF2= NYPGTY1oW0GQR1XS
human MKN1 cell NUOxNmdWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4OFEzKM7:TR?= NUC2S2tXW0GQR1XS
NCI-H1650 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3jsSGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?= MkHZV2FPT0WU
human HT-1376 cell NYKxWJROT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XafmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO MVLTRW5ITVJ?
SW872 cell NYPwUm52T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1\T[mlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1PDV7IN88US=> NUP4cIlnW0GQR1XS
human RT-112 cell NVXSe3l4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmXITY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4PDh|IN88US=> M{T1fHNCVkeHUh?=
human HT-29 cell NHj4SlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFTuOWJKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0> NWPxVlNqW0GQR1XS
human U-266 cell MlfvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFMxOiEQvF2= NVfucW84W0GQR1XS
human HEL cell NHvVfIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;hUXNNUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PTF5IN88US=> Mnz5V2FPT0WU
human KU812 cell NWnRPZlST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{T0[WlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyOTZ2IN88US=> M4DkZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01429337 Recruiting Hepatic Impairment Novartis Pharmaceuticals|Novartis March 7 2011 Phase 1
NCT03280030 Recruiting Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 6 2018 Phase 2
NCT01883362 Completed Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis February 6 2014 Phase 2
NCT02634827 Active not recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|FLT3 Tyrosine Kinase Domain Point Mutation|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Mayo Clinic|National Cancer Institute (NCI) December 30 2015 Phase 2
NCT00045942 Completed Acute Myeloid Leukemia|Myelodysplastic Syndromes Novartis Pharmaceuticals|Novartis January 30 2002 Phase 1|Phase 2
NCT03092674 Recruiting Acute Myeloid Leukemia|Adult Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 22 2017 Phase 2|Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID